Fiera Capital Corp Sells 2,843 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fiera Capital Corp lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 31.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,154 shares of the pharmaceutical company's stock after selling 2,843 shares during the quarter. Fiera Capital Corp's holdings in Vertex Pharmaceuticals were worth $2,862,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of VRTX. Quent Capital LLC boosted its stake in shares of Vertex Pharmaceuticals by 33.0% in the 1st quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company's stock valued at $167,000 after purchasing an additional 99 shares during the last quarter. Montag A & Associates Inc. raised its position in shares of Vertex Pharmaceuticals by 13.0% in the 1st quarter. Montag A & Associates Inc. now owns 435 shares of the pharmaceutical company's stock valued at $182,000 after acquiring an additional 50 shares during the period. Atomi Financial Group Inc. raised its position in shares of Vertex Pharmaceuticals by 21.5% in the 1st quarter. Atomi Financial Group Inc. now owns 882 shares of the pharmaceutical company's stock valued at $369,000 after acquiring an additional 156 shares during the period. Concurrent Investment Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 93.2% in the 1st quarter. Concurrent Investment Advisors LLC now owns 1,287 shares of the pharmaceutical company's stock valued at $538,000 after acquiring an additional 621 shares during the period. Finally, NorthRock Partners LLC raised its position in shares of Vertex Pharmaceuticals by 19.3% in the 1st quarter. NorthRock Partners LLC now owns 2,447 shares of the pharmaceutical company's stock valued at $1,023,000 after acquiring an additional 396 shares during the period. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of analyst reports. Bank of America cut their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a "buy" rating on the stock in a research report on Monday, October 14th. Barclays downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and increased their price target for the company from $472.00 to $509.00 in a research report on Monday, August 5th. Royal Bank of Canada increased their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a "sector perform" rating in a research report on Tuesday, November 5th. Truist Financial restated a "buy" rating and set a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Finally, UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $495.96.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the transaction, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Sangeeta N. Bhatia sold 646 shares of the business's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company's stock, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the business's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares of the company's stock, valued at approximately $4,987,006. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Up 2.8 %

VRTX traded up $14.29 during trading on Friday, reaching $516.74. 1,259,505 shares of the stock were exchanged, compared to its average volume of 1,100,543. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.90 and a twelve month high of $519.88. The stock has a market cap of $133.08 billion, a P/E ratio of -259.67 and a beta of 0.39. The stock's 50 day moving average price is $475.40 and its two-hundred day moving average price is $468.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.26 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the previous year, the company earned $3.67 earnings per share. The company's quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.82 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.